SCHEMBL709345

SCHEMBL709345

CC(=O)SCCCCCCC1CCC(CCCCCCSC(C)=O)C(CCCCCCSC(C)=O)C1

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.35
HDAC4 P56524 2/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC6 Q9UBN7 2/20 0.33
HDAC3 O15379 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC9 Q9UKV0 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
CYP2C19 P33261 1/20 0.31
POLB P06746 1/20 0.30
BLM P54132 1/20 0.30
ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL709019 0.94 CYP2C19 (0.32) ALOX5CYP2C19POLBBLMATM
SCHEMBL14856877 0.93 ALOX5 (0.31) ALOX5HDAC4HDAC1HDAC6
SCHEMBL14856825 0.86 CYP2C19 (0.30) CYP2C19
SCHEMBL712765 0.83 CYP2C19 (0.34) CYP2C19POLBBLMATM
SCHEMBL711396 0.83 CYP2C19 (0.34) CYP2C19POLBBLMATM
SCHEMBL709973 0.83 CYP2C19 (0.34) CYP2C19POLBBLMATM
SCHEMBL13370527 0.77 CYP2C19 (0.30) CYP2C19
SCHEMBL14856846 0.76 CYP2C19 (0.32) CYP2C19POLBBLMATM
SCHEMBL3761489 0.76 CYP2C19 (0.32) CYP2C19POLBBLMATM
SCHEMBL14856880 0.76 CYP2C19 (0.32) CYP2C19POLBBLMATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342274-B1 SULFUR-CONTAINING CYCLOALI PHATIC COMPOUND, FILLED SULFUR-VULCANIZABLE ELASTOMER COMPOSITION CONTAINING SULFUR-CONTAINING CYCLOALIPHATIC COMPOUND AND ARTICLES FABRICATED THEREFROM MOMENTIVE PERFORMANCE MAT INC (US) 2013-04-17 EP claimed
US-8124206-B2 Sulfur-containing cycloaliphatic compound, filled sulfur-vulcanizable elastomer composition containing sulfur-containing cycloaliphatic compound and articles fabricated therefrom MOMENTIVE PERFORMANCE MATERIALS, INC. (US) 2012-02-28 US claimed
WO-2010059402-A1 SULFUR-CONTAINING CYCLOALI PHATIC COMPOUND, FILLED SULFUR-VULCANIZABLE ELASTOMER COMPOSITION CONTAINING SULFUR-CONTAINING CYCLOALIPHATIC COMPOUND AND ARTICLES FABRICATED THEREFROM MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2010-05-27 WO claimed
US-20100112259-A1 Sulfur-containing cycloaliphatic compound, filled sulfur-vulcanizable elastomer composition containing sulfur-containing cycloaliphatic compound and articles fabricated therefrom MOMENTIVE PERFORMANCE MATERIALS INC. 2010-05-06 US claimed
US-8846170-B2 Sulfur-containing cycloaliphatic compound, filled sulfur-vulcanizable elastomer composition containing sulfur-containing cycloaliphatic compound and articles fabricated therefrom MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2014-09-30 US disclosed
EP-2342274-B1 SULFUR-CONTAINING CYCLOALI PHATIC COMPOUND, FILLED SULFUR-VULCANIZABLE ELASTOMER COMPOSITION CONTAINING SULFUR-CONTAINING CYCLOALIPHATIC COMPOUND AND ARTICLES FABRICATED THEREFROM MOMENTIVE PERFORMANCE MAT INC (US) 2013-04-17 EP disclosed
EP-1516010-B1 PROCESS FOR THE PREPARATION OF A CROSS-LINKED HYDROGEL BASF SE (DE) 2013-01-02 EP disclosed
US-20120116002-A1 SULFUR-CONTAINING CYCLOALIPHATIC COMPOUND, FILLED SULFUR-VULCANIZABLE ELASTOMER COMPOSITION CONTAINING SULFUR-CONTAINING CYCLOALIPHATIC COMPOUND AND ARTICLES FABRICATED THEREFROM MOMENTIVE PERFORMANCE MATERICALS INC. (US) 2012-05-10 US disclosed
US-8124206-B2 Sulfur-containing cycloaliphatic compound, filled sulfur-vulcanizable elastomer composition containing sulfur-containing cycloaliphatic compound and articles fabricated therefrom MOMENTIVE PERFORMANCE MATERIALS, INC. (US) 2012-02-28 US disclosed
EP-1613583-B1 MIXTURES OF COMPOUNDS COMPRISING AT LEAST TWO DOUBLE BONDS AND USE THEREOF BASF SE (DE) 2011-08-17 EP disclosed
EP-2345431-A2 Method for producing esters from polyalcohols BASF SE (DE) 2011-07-20 EP disclosed
EP-2345432-A2 Method for producing esters from polyalcohols BASF SE (DE) 2011-07-20 EP disclosed
WO-2004087635-A2 MIXTURES OF COMPOUNDS COMPRISING AT LEAST TWO DOUBLE BONDS AND USE THEREOF BASF AKTIENGESELLSCHAFT (DE) 2004-10-14 WO disclosed
WO-2004087790-A2 MIXTURES OF POLYALKOXYLATED TRIMETHYLOLPROPANE (METH)ACRYLATE BASF AKTIENGESELLSCHAFT (DE) 2004-10-14 WO disclosed
WO-2003104302-A1 (METH)ACRYLIC ESTERS OF POLYALKOXYLATED TRIMETHYLOLPROPANE BASF AKTIENGESELLSCHAFT (DE) 2003-12-18 WO disclosed
WO-2003104300-A1 (METH)ACRYLIC ESTERS OF POLYALKOXYLATED TRIMETHYLOLPROPANE BASF AKTIENGESELLSCHAFT (DE) 2003-12-18 WO disclosed
WO-2003104301-A1 (METH)ACRYLIC ESTERS OF POLYALKOXYLATED GLYCERINE BASF AKTIENGESELLSCHAFT (DE) 2003-12-18 WO disclosed
WO-2003104299-A1 METHOD FOR THE PRODUCTION OF ESTERS OF POLYALCOHOLS BASF AKTIENGESELLSCHAFT (DE) 2003-12-18 WO disclosed
EP-1345882-A2 METHOD FOR PRODUCING (METH)ACRYLIC ACID BASF AKTIENGESELLSCHAFT (DE) 2003-09-24 EP disclosed
WO-2002051786-A2 METHOD FOR PRODUCING (METH)ACRYLIC ACID BASF AKTIENGESELLSCHAFT (DE) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100112259-A1 Sulfur-containing cycloaliphatic compound, filled sulfur-vulcanizable elastomer composition containing sulfur-containing cycloaliphatic compound and articles fabricated therefrom CRHR2, CRH, CRHR1 ALOX5 608/4885HDAC4 3630/4885HDAC1 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.